Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-26

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Morganella morganii prosthetic joint infection of the hip. The patient has exhausted all conventional therapies, both surgical and medical, at considerable detriment to their quality of life. The treatment involves 2 intra-articular injections of bacteriophages into the joint and surrounding area and 14 days of intravenous phage therapy. The goal is to eliminate the infection and prevent further complications, providing a potential new treatment avenue for patients with difficult-to-treat infections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bacteriophage Therapy in Patients With Prosthetic Joint Infections

NCT04787250

Prosthetic Joint Infection

WITHDRAWN PHASE1/PHASE2

Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR.

NCT06605651

Hip Prosthesis Infection Knee Prosthesis Infection

NOT_YET_RECRUITING PHASE2

Comparison of BioCart™II With Microfracture for Treatment of Cartilage Defects of the Femoral Condyle

NCT00729716

Symptomatic Cartilage Defects of the Femoral Condyle

UNKNOWN PHASE2

Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)

NCT05137314

Joint Infection

COMPLETED PHASE1

Joint Microbiome Study for the Knee

NCT05254145

Knee Osteoarthritis PJI

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prosthetic Joint Infections of Hip

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single patient

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label Arm

Bacteriophage drug product

Group Type EXPERIMENTAL

phage therapy

Intervention Type BIOLOGICAL

Single anti-Morganella morganii bacteriophage drug product

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

phage therapy

Single anti-Morganella morganii bacteriophage drug product

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of active chronic prosthetic joint infection
* Causative bacteria is susceptible to bacteriophage therapy in vitro
* History of multiple failed antibiotic and surgical interventions